JP2008301828A5 - - Google Patents

Download PDF

Info

Publication number
JP2008301828A5
JP2008301828A5 JP2008176378A JP2008176378A JP2008301828A5 JP 2008301828 A5 JP2008301828 A5 JP 2008301828A5 JP 2008176378 A JP2008176378 A JP 2008176378A JP 2008176378 A JP2008176378 A JP 2008176378A JP 2008301828 A5 JP2008301828 A5 JP 2008301828A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
amino acid
thymidine kinase
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008176378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008301828A (ja
JP5070145B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2008301828A publication Critical patent/JP2008301828A/ja
Publication of JP2008301828A5 publication Critical patent/JP2008301828A5/ja
Application granted granted Critical
Publication of JP5070145B2 publication Critical patent/JP5070145B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008176378A 1997-10-14 2008-07-04 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 Expired - Fee Related JP5070145B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6181297P 1997-10-14 1997-10-14
US60/061,812 1997-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000516019A Division JP2002516061A (ja) 1997-10-14 1998-10-14 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000673A Division JP2012115270A (ja) 1997-10-14 2012-01-05 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質

Publications (3)

Publication Number Publication Date
JP2008301828A JP2008301828A (ja) 2008-12-18
JP2008301828A5 true JP2008301828A5 (enExample) 2009-11-12
JP5070145B2 JP5070145B2 (ja) 2012-11-07

Family

ID=22038301

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000516019A Withdrawn JP2002516061A (ja) 1997-10-14 1998-10-14 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
JP2008176378A Expired - Fee Related JP5070145B2 (ja) 1997-10-14 2008-07-04 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
JP2012000673A Withdrawn JP2012115270A (ja) 1997-10-14 2012-01-05 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000516019A Withdrawn JP2002516061A (ja) 1997-10-14 1998-10-14 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000673A Withdrawn JP2012115270A (ja) 1997-10-14 2012-01-05 チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質

Country Status (7)

Country Link
US (7) US7888091B2 (enExample)
EP (3) EP1025212B1 (enExample)
JP (3) JP2002516061A (enExample)
AT (1) ATE374247T1 (enExample)
CA (1) CA2306443A1 (enExample)
DE (1) DE69838483T2 (enExample)
WO (1) WO1999019466A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2306443A1 (en) * 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
AU783845B2 (en) * 2000-05-12 2005-12-15 Wolfgang Knecht Novel deoxynucleoside kinase enzyme variants
AU2001296864A1 (en) 2000-08-31 2002-03-13 Mayo Foundation For Medical Education And Research Detection of varicella-zoster virus
WO2002061390A2 (en) * 2001-01-31 2002-08-08 Mayo Foundation For Medical Education And Research Detection of herpes simplex virus
US7691571B2 (en) 2001-01-31 2010-04-06 Mayo Foundation For Medical Education And Research Detection of bordetella
US7439271B2 (en) 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
WO2003100045A1 (en) * 2002-05-23 2003-12-04 Wolfgang Knecht Plant thymidine kinases and their use
NZ536623A (en) 2002-05-23 2006-05-26 Wolfgang Knecht Plant thymidine kinases and their use
US7074598B2 (en) 2002-09-25 2006-07-11 Mayo Foundation For Medical Education And Research Detection of vancomycin-resistant enterococcus spp.
US7365176B2 (en) 2002-09-26 2008-04-29 Mayo Foundation For Medical Education And Research Detection of Epstein-Barr virus
US7074599B2 (en) 2002-09-27 2006-07-11 Mayo Foundation For Medical Education And Research Detection of mecA-containing Staphylococcus spp.
US7427475B2 (en) 2003-11-18 2008-09-23 Mayo Foundation For Medical Education And Research Detection of group B streptococcus
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CN103930543B (zh) 2011-09-06 2020-11-27 诺维信公司 葡糖淀粉酶变体和编码它们的多核苷酸
ES2900102T3 (es) * 2013-02-20 2022-03-15 Univ Emory Composiciones para la secuenciación de ácidos nucleicos en mezclas
JP2016524590A (ja) * 2013-03-14 2016-08-18 エペイウス バイオテクノロジーズ コーポレイション 遺伝子療法適用のためのチミジンキナーゼ診断アッセイ
US9701985B2 (en) 2013-06-04 2017-07-11 Virginia Commonwealth University mda-9/syntenin promoter to image and treat metastatic cancer cells
US9951114B2 (en) 2013-06-04 2018-04-24 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
WO2014209553A1 (en) 2013-06-04 2014-12-31 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
US9454494B2 (en) * 2014-08-01 2016-09-27 Honeywell International Inc. Encrypting a communication from a device
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11542524B2 (en) * 2017-11-29 2023-01-03 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2019200013A1 (en) 2018-04-11 2019-10-17 Cancer Targeting Systems, Inc. Therapeutic constructs for treating cancer
US11685904B2 (en) * 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN109735571A (zh) * 2019-03-11 2019-05-10 四川药智联恒科技有限公司 双自杀基因慢病毒表达载体及其应用
KR20240099339A (ko) * 2021-10-25 2024-06-28 젠비보, 인크. 치료제 전달을 위한 조성물 및 방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4514497B1 (en) 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8914543D0 (en) 1989-06-23 1989-08-09 Parker David Chemical compounds
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0675962B1 (en) 1992-12-23 2003-02-05 Arch Development Corporation Synthetic herpes simplex virus promoters
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0722493A1 (en) 1993-07-27 1996-07-24 THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Modified dna virus vectors and uses therefor
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0758387B1 (en) * 1994-05-02 2001-12-19 University of Washington Thymidine kinase mutants
FR2723962B1 (fr) * 1994-08-25 1996-10-31 Univ Paris Curie Hsv1-tk modifiee fonctionnelle
EP0879288A1 (fr) * 1996-02-09 1998-11-25 Aventis Pharma S.A. Variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2746016B1 (fr) * 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
CA2306443A1 (en) * 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities

Similar Documents

Publication Publication Date Title
Bergman et al. Overexpressed Csk tyrosine kinase is localized in focal adhesions, causes reorganization of αvβ5 integrin, and interferes with HeLa cell spreading
AU2003215869B2 (en) Hybrid and single chain meganucleases and use thereof
Acker et al. Interactions between the human RNA polymerase II subunits
ES2552095T3 (es) Un receptor de superficie de linfocitos que se une a CAML, ácidos nucleicos que lo codifican y métodos de uso del mismo
US7008780B2 (en) Chimeric DNA-binding proteins
Li et al. ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression
Vestal The guanylate-binding proteins (GBPs): proinflammatory cytokine-induced members of the dynamin superfamily with unique GTPase activity
Feuerbach et al. Identification of amino acids within the MHC molecule important for the interaction with the adenovirus protein E3/19K.
PL178402B1 (pl) Sekwencja nukleotydowa, wektor zawierający sekwencję nukleotydową i kompozycje farmaceutyczne
Kandala et al. Cloning of Rous Sarcoma Virus Enhancer Factor Genes: I. Evidence That RSV-EF-1 Is Related to Y-Box (Inverted CCAAT) Binding Proteins and Binds to Multiple Motifs in the RSV Enhancer
Shen et al. Intracellular association of FGF-2 with the ribosomal protein L6/TAXREB107
Liao et al. Identification of two amino acids within the EIIIA (ED-A) segment of fibronectin constituting the epitope for two function-blocking monoclonal antibodies
US6824971B1 (en) Methods of inhibiting or enhancing the TGFβ-SMAD signaling pathway
EP1194569A2 (en) Seripancrin
ES2231537T3 (es) Un nuevo miembro de la familia de receptores epha.
Vaishnav et al. The molecular and functional characterization of E2F-5 transcription factor
Sunstrom et al. Determination of the origin-specific DNA-binding domain of polyomavirus large T antigen
JP2002511735A (ja) アダプター蛋白質ｆｒｓ２および関連する物質および方法
Hughes et al. Cloning and Chromosomal Localization of a Mouse cDNA with Homology to theSaccharomyces cerevisiaeGene Zuotin
EP0871711A1 (en) Compositions and methods for site-directed integration into dna
CA2339529C (en) Isolated and purified human soluble guanylyl cyclase .alpha.1/.beta.1 (hsgc .alpha.1/.beta.1)
EP0938559A2 (en) HUMAN POLYHOMEOTIC 2 (hph2) ACTS AS A TUMOR SUPPRESSOR
JP2010538093A5 (enExample)
Reichman Cloning, characterization and oncogenic activation of a c-crk proto-oncogene.
WO1997015318A1 (en) Peptide inhibitors of a phosphotyrosine-binding domain containing protein